F-star enters into strategic collaboration to develop bispecific antibodies in immuno-oncology
F-star, a biopharmaceutical company developing bispecific antibody immuno-oncology products, has announced a new partnership with a leading science and technology company. This new strategic collaboration will focus on the development and commercialisation of five bispecific immuno-oncology antibodies, including F-star’s preclinical lead asset FS118. The deal, potentially worth over €1 billion, will also see F-star receive up to €115 million in upfront, R&D funding and milestone payments in the first two years. This collaboration will support their mission to transform the treatment of cancer.